Article Abstract

Additive effects of atezolizumab and bevacizumab plus chemotherapy for patients with non-small cell lung cancer regardless of presence of EGFR mutations, ALK rearrangements, or PD-L1 expression

Authors: Takehiro Uemura, Toyoaki Hida


The first-line treatment protocol for advanced non-small cell lung cancer (NSCLC) has improved with immune checkpoint inhibitor (ICI) development. The Food and Drug Administration (FDA) has approved three ICIs for second-line treatment of NSCLC (nivolumab, pembrolizumab, and atezolizumab), and randomized studies have shown superior overall survival (OS) with ICIs compared with second-line docetaxel (1-4).